DDrare: Database of Drug Development for Rare Diseases

Losartan and nebivolol (DrugBank: Losartan, Nebivolol)

3 diseases

ID	Disease name (Link within this page)	Number of trials
17	Multiple system atrophy	0
113	Muscular dystrophy	0
167	Marfan syndrome	1

17. Multiple system atrophy [ 107 clinical trials, 153 drugs, (DrugBank: 48 drugs), 59 drug target genes, 104 drug target pathways]

Searched query = "Multiple system atrophy", "MSA-C", "MSA-P", "Olivopontocerebellar atrophy", "OPCA", "Striatonigral degeneration", "Shy-Drager syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: . Trials are sorted by Date_enrollment from most recent to oldest in the table.

0 / 107 trial found

113. Muscular dystrophy [ 567 clinical trials, 442 drugs, (DrugBank: 93 drugs), 55 drug target genes, 151 drug target pathways]

Searched query = "Muscular dystrophy", "Dystrophinopathies", "Myotilinopathy", "Laminopathy", "Caveolinopathy", "LGMD1C", "Desminopathy", "Sarcoglycanopathy", "α-dystroglycanopathy", "FCMD", "Walker-Warburg syndrome", "Muscle-eye-brain disease", "Myotonic dystrophy", "Integrin α7 deficient CMD", "Rigid spine syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: . Trials are sorted by Date_enrollment from most recent to oldest in the table.

0 / 567 trial found

167. Marfan syndrome [ 19 clinical trials, 38 drugs, (DrugBank: 10 drugs), 10 drug target genes, 49 drug target pathways]

Searched query = "Marfan syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 19 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00683124 (ClinicalTrials.gov)	July 2008	21/5/2008	Nebivolol Versus Losartan Versus Nebivolol+Losartan Against Aortic Root Dilation in Genotyped Marfan Patients	Effects of Losartan vs. Nebivolol vs. the Association of Both on the Progression of Aortic Root Dilation in Marfan Syndrome (MFS) With FBN1 Gene Mutations.	Marfan Syndrome	Drug: Losartan and nebivolol;Drug: Losartan;Drug: Nebivolol	IRCCS Policlinico S. Matteo	Merck Sharp & Dohme Corp.;Menarini Group	Recruiting	12 Months	55 Years	Both	291	Phase 3	Italy